Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 21, 2009

Debiopharm’s Sexual Deviation Treatment Gets Swiss Approval

  • Swiss regulatory authorities has given Debiopharm’s therapy for sexual deviations the go-ahead. Initial discussions with potential marketing partners for Switzerland are in progress.

    The injectable GnRH agonist analogue, Moapar®, is indicated for use once every three months in the reversible reduction of serum testosterone in men diagnosed with this disdorder. Used in combination with psychotherapy, it cuts serum testosterone down to castration levels.

    The treatment was recently launched in Germany and Belgium as Salvacyl®. It is also sanctioned in France, the U.K., Sweden, Norway, Denmark, The Netherlands, and Finland via the European Mutual Recognition Procedure. Debiopharm says that the drug will be launched progressively in European countries by its commercial partners during 2009 and 2010. 

    The company claims clinical trials have shown Salvacyl/Moapar has fewer side effects than antiandrogens, including a lower risk of hepatocellular damage, thromboembolism, and gynecomastia.

     

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »